OGT significantly expands global reach


Expansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes

OGT, a Sysmex Group company, announces that it is rapidly increasing its international reach, benefitting more regions with access to the company’s renowned clinical genomics solutions, expertise and technical support network. OGT has been working closely with Sysmex group companies and new distributors to achieve this, and all new and existing sales channels will now cover CytoSure® and SureSeq™ microarray and next generation sequencing (NGS) in addition to CytoCell® fluorescence in situ hybridisation (FISH) products. This move is a significant step forward on OGT’s mission to help improve clinical care by working in close partnership with its customers.

Committed to providing access to its solutions and expertise no matter where a customer is located, OGT has further added 14 more to its list of 57 countries it provides products to over the last 2 years. Recent additions include Sysmex Germany and Sysmex Partec Italia, which started supplying OGT products and services to these regions from 1 April 2022.

To ensure that customers continue to receive the highest level of expertise and above-and-beyond support that the company is well known for, OGT is dedicated to providing distributors and Sysmex group companies with first-class training and assistance. Jesús López-Belmonte PhD, Business Sector Manager Cytogenetics Life Science at Sysmex España reflected, ‘During the last ten years, I’ve worked with multiple well-known companies in the cytogenetics space, but I have to say that I have never encountered such a level of client commitment as I have seen from OGT. The team always provides me with all the tools to support our customers, whenever I ask for help. The phrase “we will help you get the right results” reaches a new level with this team – they are always willing to help and collaborate.’

This commitment to global support, knowledge sharing and partnership is further evidenced by OGT’s highly successful Clinical Education webinar series. This ongoing educational series has already reached close to 1000 participants in more than 20 countries, covering a range of topics from disease overviews to the latest research and testing criteria. The growing success of this knowledge-sharing series reflects the company’s dedication to partnering with customers to better harness genomic analysis and improve patient outcomes. Reflecting on OGT’s expanding reach, Tori Anthony-Dubernet, Director of European Sales and Support at OGT said: ‘We are thrilled that we’ve been able to increase access to our clinical support network and genomics solutions so rapidly and successfully. Through sharing our clinical expertise, technology and technical support, we have already seen how we can make a big impact on outcomes in new regions. I’m always delighted to see when we can help to implement better testing because it’s all about improving patient healthcare and outcomes. At OGT, we’re passionate about making a difference and our pledge to equip more countries with not only our technology, but most importantly, our support and guidance will help to achieve this.’


About Oxford Gene Technology IP Limited

OGT, a Sysmex Group company, with offices in Oxford and Cambridge, UK, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists – including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers – not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership – together – we’ll achieve more. For more information, visit www.ogt.com.

CytoCell® FISH probes are CE IVD for laboratory professional use only. Not intended for use as stand-alone diagnostics or companion diagnostics. Therapeutic action should not be initiated on the basis of the FISH result alone. CytoSure®, SureSeq™ and CytoCell myProbes®: For Research Use Only, not for use in diagnostic procedures. Product availability may vary from country to country and is subject to varying regulatory requirements. Contact your local representatives for availability.


About Sysmex Europe SE

Sysmex supports healthcare professionals around the world in lighting the way with diagnostics by providing a broad range of medical diagnostics products and solutions. In the fields of haematology, urinalysis, haemostasis, life science, flow cytometry, essential healthcare and now immunochemistry, we combine highly dependable, multi-functional and easy-to-operate instruments, a variety of reagents and software, plus reliable service and support.

Sysmex Europe SE, located near Hamburg, Germany, is a subsidiary of the Sysmex Corporation from Kobe, Japan. From our Hamburg offices, we serve our affiliates, distributors and customers throughout Europe, the Middle East, and Africa (EMEA). For more information, visit www.sysmex-europe.com

Copyright © Sysmex Europe SE. All rights reserved.